Albuquerque, New Mexico--(Newsfile Corp. - February 20, 2023) - DXD Capital, a data-driven real estate and private equity firm based in Albuquerque, NM, is seeking to capitalize on the strong ...
The antibody-drug conjugate trastuzumab deruxtecan (T-DXd, Enhertu) proved active in a phase II study of advanced HER2-positive colorectal cancer (CRC). Almost 40% of patients treated with the ...
New analysis of the DESTINY-Breast06 trial demonstrated that trastuzumab deruxtecan (T-DXd) provides meaningful clinical benefit regardless of time to progression on prior endocrine therapy, offering ...
In the article that accompanies this editorial, Rugo et al 5 review the real-world practices for the management of T-DXd–related ILD in breast cancer, providing helpful advice on strategies aimed at ...
BERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in different HER2-positive early-stage breast cancer settings in back-to-back ...
Patient undergoing chemotherapy. Trastuzumab deruxtecan improves overall survival vs trastuzumab emtansine in previously treated, HER2-positive, advanced breast cancer, a phase 3 trial suggests.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback